Full text is available at the source.
Abstract
Oncolytic viruses can target multiple steps within the cancer-immunity cycle.
- Oncolytic viruses directly destroy tumour cells, releasing soluble antigens and signals that promote immune responses against cancer.
- These viruses may enhance the recruitment of T cells into areas of tumours that are usually resistant to immune attack.
- Some oncolytic viruses can be modified to deliver therapeutic genes, potentially improving treatment efficacy.
- They can also use existing tumours as sources for neoantigen vaccination, which might help eliminate distant, untreated tumours.
- These characteristics suggest that oncolytic viruses could be valuable in combination therapies for improving cancer immunotherapy.
Simplified